TRIAL DATA
BRAF-directed therapy outperforms EGFR inhibition in metastatic BRAF-mutant CRCMeta-analysis of 18 randomized trials (11,931 participants) found pooled median overall survival of 22.3 months for BRAF-directed regimens versus 10.1 months for EGFR-directed therapy in first-line treatment. (Journal of Gastrointestinal Cancer)